Dofetilide

Quick links to important sections

Dofetilide

Selected form

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dofetilide

Property Description
Active Ingredient Dofetilide
Form Capsule (oral)
Pharmacological Class Class III Antiarrhythmic Agent
General Purpose Stabilization of heart rhythm
Origin Synthetic (Methanesulfonanilide Derivative)

What Type of Medicine is Dofetilide?

Dofetilide is a specialized, synthetic cardiovascular medication classified as an antiarrhythmic agent. It is specifically designated as a Class III antiarrhythmic under the Vaughan Williams Classification, establishing its primary role in regulating the heart's electrical system. Dofetilide is a single-ingredient, prescription-only drug chemically defined as a methanesulfonanilide derivative. Pharmacological studies confirm its high degree of selectivity for the electrical channels it targets.

This medication is uniquely differentiated by being recognized as one of the purest Class III agents available, meaning its mechanism is highly focused on a single type of electrical process. This specificity provides clinicians with a targeted tool for electrophysiology-directed therapy, focusing solely on the potassium current channels and minimizing action on other major ion pathways.

Composition and General Therapeutic Purpose

The active ingredient is Dofetilide, supplied for oral administration in a capsule formulation, frequently utilized as Dofetilide fumarate. This oral delivery ensures the drug is reliably absorbed into the bloodstream, where it exerts its effects on heart muscle cells.

The general therapeutic purpose of Dofetilide is the stabilization and maintenance of a steady heart rhythm. By specifically delaying repolarization, the drug increases the time required for heart tissue to reset electrically between beats. This mechanism stabilizes the heart's electrical cycle. This targeted electrophysiological action contributes to the overall goal of maintaining normal sinus rhythm, which is a key component in the management of specific rhythm disturbances.

Regulatory References

  1. Dofetilide (LiverTox - NIH)
  2. Dofetilide (Union Register)

What side effects are possible with Dofetilide?

Possible Side Effects and Safety Information

The information in this section is derived strictly from official government regulatory documents and prescribing information for dofetilide, focusing on documented adverse reactions and mandatory safety constraints.

Serious Adverse Reactions and Monitoring

The most critical safety risk documented for dofetilide is the potential to cause new or worsened ventricular arrhythmias, most notably Torsade de Pointes (TdP), a life-threatening form of ventricular tachycardia. This risk is dose-related and associated with excessive QT interval prolongation.

Due to this risk, regulatory agencies mandate that the initiation and re-initiation of dofetilide therapy must occur in a facility capable of providing continuous ECG monitoring for a minimum of three days, as the risk of TdP is highest during this initial period.

Common Adverse Reactions

The following non-serious adverse events have been officially listed in regulatory labeling as common (occurring in 1%–10% of patients in clinical studies) or very common (ge10% in some studies) and are grouped by the affected System-Organ Class (SOC):

System/Organ Class (SOC) Representative Adverse Reactions
Nervous System Headache (Very Common), Dizziness, Insomnia
Cardiac Chest Pain, Bradycardia, Ventricular Tachycardia
Gastrointestinal Nausea, Diarrhea, Abdominal Pain
Respiratory Respiratory Tract Infection, Dyspnea (Shortness of Breath)

Population-Specific Restrictions

Dofetilide is officially contraindicated in patients with a baseline long QTc interval (typically >440 msec in most patients) or those with severe renal impairment (Creatinine Clearance <20 mL/min). Furthermore, Hypokalemia and Hypomagnesemia must be corrected before starting treatment, as these electrolyte imbalances increase the risk of TdP, a safety requirement explicitly stated in official labeling. Safety and effectiveness have not been established in the pediatric population.

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section is based exclusively on official regulatory prescribing documents and addresses the documented manifestations and required emergency actions in case of dofetilide overdose.

Overdose with dofetilide is defined as an intensification of its primary effect, which can result in the most serious adverse reaction: excessive lengthening of the QT interval.

Documented Manifestation Severe Outcome Risk
Excessive QT Prolongation Torsade de Pointes (TdP)
Proarrhythmic effects Ventricular Fibrillation

Required Emergency Actions

The most important regulatory instruction is to immediately contact emergency services or a healthcare provider if a suspected overdose occurs, or if symptoms associated with a heart rhythm problem are present. The official labeling emphasizes that even a single extra capsule can lead to serious proarrhythmia.

  • No Specific Antidote: There is no specific antidote for dofetilide overdose.
  • Continuous Monitoring: Immediate and continuous Electrocardiogram (ECG) monitoring is required in a hospital setting due to the risk of life-threatening arrhythmias.
  • Supportive Management: Treatment is supportive and symptomatic. This includes correcting electrolyte imbalances, such as low potassium or magnesium, which are known risk factors for TdP. Procedures like gastric lavage or administration of activated charcoal slurry may be considered if ingestion was very recent.

Individuals with decreased creatinine clearance (impaired kidney function) are noted to be at a higher risk for overdose-related effects due to reduced drug clearance.

Therapeutic Uses of Dofetilide

Main Uses of Dofetilide

Dofetilide is a specialized antiarrhythmic medication primarily used to manage specific types of irregular heart rhythms originating in the upper chambers of the heart, known as the atria. It belongs to a class of drugs that work by stabilizing the electrical activity within the heart tissue.

Atrial Fibrillation and Atrial Flutter

The primary applications for dofetilide include:

  • Conversion to Normal Sinus Rhythm: It is used to convert atrial fibrillation or atrial flutter into a normal, steady heartbeat. This process is known as chemical cardioversion.
  • Maintenance of Normal Sinus Rhythm: For individuals who have already been converted to a normal heart rhythm, dofetilide is used to help prevent the recurrence of these arrhythmias over the long term.

Benefits of Treatment

By helping the heart maintain a consistent and regular rhythm, dofetilide therapy aims to improve the efficiency of the heart's pumping action.

Symptom Management

Stabilizing the heart rhythm can lead to a significant reduction in the symptoms associated with atrial arrhythmias. Patients may experience a decrease in:

  • Heart palpitations or a sensation of a racing heart.
  • Shortness of breath, especially during physical activity.
  • General fatigue or weakness caused by inefficient blood flow.
  • Dizziness or lightheadedness.

Improved Quality of Life

Maintaining a normal sinus rhythm can enhance a person's ability to engage in daily activities and exercise. By preventing the heart from beating too fast or irregularly, the medication helps ensure that the body receives a more consistent supply of oxygenated blood, which can contribute to overall physical well-being and a reduction in the discomfort caused by chronic arrhythmia episodes.

Regulatory References

  1. NIH MedlinePlus overview of Dofetilide

Eligibility and Restrictions for Use

Dofetilide is an antiarrhythmic drug with strict eligibility rules established by regulatory bodies to minimize the risk of serious ventricular arrhythmias, such as Torsade de Pointes. Initiation or re-initiation of Dofetilide must occur in a facility with continuous ECG monitoring and cardiac resuscitation capabilities for a minimum of three days.

Contraindicated Populations and Conditions

Use is prohibited for patients with:

  • Long QT Syndromes: Congenital or acquired long QT syndromes.
  • Prolonged Baseline QT Interval: A baseline QT interval or QTc greater than 440 msec (or greater than 500 msec in patients with ventricular conduction abnormalities).
  • Severe Renal Impairment: Calculated creatinine clearance of less than 20 mL/min.
  • Hypersensitivity: A known hypersensitivity to the medicine.
  • Concomitant Medications: Co-administration with specific drugs that significantly increase Dofetilide plasma concentrations, including verapamil, cimetidine, trimethoprim (alone or with sulfamethoxazole), ketoconazole, prochlorperazine, dolutegravir, megestrol, or hydrochlorothiazide (alone or with triamterene).

Special Eligibility Considerations

  • Renal Impairment: Dosage must be adjusted based on the patient's calculated creatinine clearance if it is 20–60 mL/min.
  • Electrolytes: Hypokalemia (low potassium) and hypomagnesemia (low magnesium) must be corrected to the normal range prior to and maintained during therapy.
  • Pediatric Use: Safety and effectiveness in pediatric patients have not been established.
  • Pregnancy/Lactation: Use during pregnancy is not recommended unless the potential benefit outweighs the risk to the fetus. Use during lactation is not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dofetilide's interaction profile is critically important and largely governed by its primary route of elimination via the renal cationic transport system and its effect on the heart's QT interval.


Contraindicated Combinations

The simultaneous use of dofetilide with certain medications is strictly forbidden due to a high risk of increasing dofetilide levels (exposure) or causing dangerous additive cardiac effects. These include, but are not limited to:

  • Renal Cation Transport Inhibitors: Cimetidine, Trimethoprim (including co-trimoxazole), Ketoconazole, Verapamil, Hydrochlorothiazide (alone or with Triamterene), Megestrol, Prochlorperazine, and Dolutegravir.
  • Other Antiarrhythmics: All other Class I and Class III antiarrhythmic agents, as well as any other drug known to prolong the QT interval.

Other Significant Interactions

Interactions that require specific management or avoidance are:

  • Potassium-Depleting Drugs: Medications that can lower potassium or magnesium levels (e.g., certain diuretics or Amphotericin B) should only be used if the electrolyte imbalance is corrected beforehand. Low electrolyte levels increase the risk of serious heart rhythm problems.
  • Timing Requirements: If switching from other Class I or III antiarrhythmic agents, specific waiting periods (withholding for several half-lives) are necessary before starting dofetilide.
  • Food Products: Grapefruit and grapefruit juice should be avoided as they may affect the amount of dofetilide absorbed by the body.

Mechanism of Action

Dofetilide modulates the electrical activity of heart muscle cells (myocytes) by influencing specific ion currents that regulate the cardiac action potential. It achieves this effect through highly selective action on specific potassium ion channels.


Selective Blockade of Cardiac Potassium Channels

Dofetilide engages the cellular mechanisms that govern the final phase of the cardiac electrical cycle. It selectively blocks the rapid component of the delayed rectifier potassium current (IKr), which is primarily responsible for the repolarization of the myocardial cell after excitation. By targeting the human ether-à-go–go–related gene (hERG) channel that carries this current, Dofetilide modifies a key signaling sequence in the action potential.


Prolongation of the Effective Refractory Period

Modifying this early molecular step—the IKr blockade—slows the efflux of potassium ions out of the heart cells. This delay prolongs the duration of the action potential and, consequently, the effective refractory period within the atria and ventricles. This prolongation alters the electrophysiological substrate, increasing the threshold for re-entry and reducing the excitability of myocardial tissue.

Dosage and Administration Information

How Dofetilide is used

Dofetilide is administered according to a highly standardized protocol to ensure proper dosing and monitoring. The medicine is supplied as a capsule and is taken orally.

Official Administration Protocol

Dofetilide therapy is initiated and dose-adjusted in a controlled hospital setting. Patients require continuous electrocardiogram (ECG) monitoring for a minimum of three days (72 hours).

Instruction Entity Administration Guideline
Route of Administration Oral administration (PO) only.
Dosing Frequency Taken twice daily (every 12 hours).
Timing with Food May be taken with or without food.
Missed Dose Rule If a dose is missed, the patient must not double the next dose; continue with the next scheduled dose.

Determining the Starting Dose

Establishing the correct dose is a procedural process determined by two factors while the patient is in the hospital. The starting dose is individualized based on the patient's calculated creatinine clearance (CrCl), which measures kidney function, and the baseline QTc interval.

Creatinine Clearance (CrCl) Recommended Starting Dose
> 60 mL/min 500 micrograms (mu g) twice daily
40 to 60 mL/min 250 mu g twice daily
20 to < 40 mL/min 125 mu g twice daily

Dose Adjustment and Follow-up

During the in-patient phase, the medical team uses continuous ECG monitoring and the measured QTc interval to determine the final, stable dose. If the QTc increases beyond a specified threshold, the dose must be decreased. Dofetilide is not to be used if the patient's creatinine clearance is less than 20 mL/min.

Recent Clinical Evidence

Dofetilide is a Class III antiarrhythmic agent primarily investigated for its role in converting and maintaining normal sinus rhythm in patients with atrial fibrillation and atrial flutter.

Conversion and Maintenance of Sinus Rhythm

Clinical trials have focused on two key areas: converting an irregular heart rhythm (cardioversion) and preventing its recurrence (maintenance).

  • Conversion Rates: Studies found that dofetilide use was associated with conversion of atrial fibrillation/flutter to normal sinus rhythm in a portion of patients over a defined period. The conversion rate observed in trials was significantly higher than that seen with placebo.
  • Maintenance of Rhythm: Following cardioversion (either pharmacological or electrical), trials showed that patients receiving dofetilide had a higher probability of maintaining normal sinus rhythm over a year compared to those receiving a placebo. The ability to maintain this rhythm was often related to the administered dose.

Safety in High-Risk Populations

A major area of research for dofetilide has centered on its safety profile in patients with structural heart disease, a population where some other antiarrhythmic agents are associated with increased mortality.

Study Focus Key Finding Summary
DIAMOND Trials Across long-term trials in patients with congestive heart failure or recent myocardial infarction, dofetilide did not increase the risk of all-cause mortality compared to placebo.
Proarrhythmia Risk The drug is known to prolong the QT interval, which carries a risk of a life-threatening arrhythmia (Torsades de Pointes). This risk is highest during the first three days of use and necessitates strict inpatient monitoring and dose adjustment based on kidney function and the QTc interval.
Hemodynamic Effects Studies indicated that dofetilide had no significant negative effect on myocardial contractility or left ventricular function in patients with structural heart disease.

Frequently Asked Questions (FAQ)

Common questions about Dofetilide (FAQ)


Q: Is Dofetilide used for all types of irregular heart rhythms?

According to the official prescribing information, Dofetilide is indicated specifically for the treatment of atrial fibrillation and atrial flutter. Its use is to convert these specific irregular rhythms back to a normal sinus rhythm and to help maintain that steady rhythm afterward.


Q: How quickly does Dofetilide start to work?

Official regulatory documents indicate that the period when the drug is reaching a stable, effective level in the body, and when the risk of serious side effects is highest, is during the first three days (72 hours). This is why continuous monitoring is required during the initial phase of treatment.


Q: What is the longest period someone typically stays on Dofetilide?

Dofetilide is used to help maintain a stable heart rhythm after conversion. Clinical trials have evaluated the drug's effectiveness for maintenance over extended periods, including up to 12 months and beyond, indicating its use in long-term therapy is evaluated in regulatory research.


Q: What kind of specialist usually prescribes Dofetilide?

The initiation process, which requires continuous ECG monitoring in a specialized setting, is generally managed by specialized clinicians in a controlled hospital environment, such as cardiologists or electrophysiologists. This strict protocol is designed to mitigate the initial risks associated with treatment.


Q: Are there different brand names for Dofetilide?

Yes, Dofetilide is the generic name for the active ingredient. In the United States, the medicine is available under the brand name Tikosyn, as noted in official drug labeling.


Q: Can Dofetilide affect my ability to drive or operate machinery?

Official guidance notes that due to the potential for side effects like dizziness and headache, individuals should determine how the medicine affects them before performing tasks like driving or operating machinery. These effects are listed as adverse reactions in official labeling.


Q: Can drinking grapefruit juice affect how Dofetilide works?

Regulatory information explicitly states that consuming grapefruit and grapefruit juice must be avoided while taking this medicine. This is because consuming grapefruit can impact the concentration of Dofetilide in the bloodstream, which may increase the potential for serious heart-related side effects.


Q: What if I occasionally drink alcohol while taking Dofetilide?

Official labeling does not provide specific restrictions regarding occasional alcohol use. However, general patient counseling for many medications suggests reviewing the use of alcohol with a healthcare professional.


Q: Can Dofetilide be used by people with a history of heart failure?

Yes. Clinical research, including the DIAMOND studies reviewed by regulatory bodies, specifically examined the use of Dofetilide in patients with conditions like congestive heart failure. These studies indicated that the drug did not increase the risk of all-cause mortality in this high-risk patient group compared to a placebo.


Q: Can taking Dofetilide make me feel tired or dizzy?

Official documentation lists dizziness and headache as common adverse reactions. While 'dizziness' is common, other central nervous system effects are reported that may be perceived as tiredness or fatigue.


Q: Is weight gain a common side effect mentioned in the Dofetilide patient information?

Weight gain is not explicitly listed as a common side effect (occurring in 1%–10% of patients). However, official labeling notes edema (fluid retention) as a known adverse event.


Q: Does Dofetilide interact with common blood pressure medications?

Yes, it is documented to interact with certain blood pressure medicines. The official label specifically lists some diuretics, such as hydrochlorothiazide, and certain calcium channel blockers, such as verapamil, as strictly forbidden combinations due to a high risk of serious interaction.


Q: Is Dofetilide safe to use during pregnancy, according to official guidelines?

Official guidelines state that use during pregnancy is not recommended unless the potential benefit to the mother is considered to outweigh the potential risk to the fetus. This statement is based on animal studies that showed adverse developmental effects.


Q: Is it possible to take Dofetilide long-term?

Yes, Dofetilide is indicated for the maintenance of normal sinus rhythm. Clinical trials have tracked its use over extended periods, showing it can be part of a long-term therapeutic plan for managing specific heart rhythm problems.


Q: Is Dofetilide the same type of drug as Amiodarone?

Both Dofetilide and Amiodarone are classified as Class III antiarrhythmic agents. However, regulatory documents list Amiodarone as an agent that must be avoided when Dofetilide therapy is being initiated.


Q: Are there any dietary restrictions I need to follow while on Dofetilide?

The only specific food restriction mentioned in official regulatory documents is the avoidance of grapefruit and grapefruit juice. No other general dietary restrictions are mandated in the core prescribing information.


Q: Does the risk of serious side effects change over time with Dofetilide?

Yes. The risk of the most serious side effect, a dangerous heart arrhythmia called Torsade de Pointes, is stated to be significantly highest during the first three days of therapy when the dose is being established and closely monitored in the hospital.


Q: How is Dofetilide cleared from the body?

Dofetilide is primarily cleared from the body by the kidneys through a specific process called the renal cationic transport system. This pathway is highly important, which is why a patient's kidney function must be precisely checked to help determine the starting dose.


Q: Can I stop taking Dofetilide if I feel better?

Official patient counseling information highlights that Dofetilide should not be discontinued without consultation with a healthcare professional, as stopping the medication abruptly may lead to the return of the irregular heart rhythm.


Q: Are children or adolescents able to use Dofetilide?

According to official regulatory labeling, the safety and effectiveness of Dofetilide have not been established in the pediatric population, which includes children and adolescents.


Q: What are the signs of a Dofetilide interaction I should be aware of?

Signs that may indicate a dangerous interaction or side effect, as noted in the patient information, include unusual dizziness, fainting, or a fast, pounding, or highly irregular heartbeat.


Q: Does Dofetilide interact with medications for depression or anxiety?

Yes, Dofetilide is known to interact with certain antidepressant medications, such as citalopram, escitalopram, and fluoxetine. Regulatory documents state that these combinations carry an increased risk of serious heart rhythm problems.


Q: What is the long-term risk profile of Dofetilide as described in research?

Long-term research, including the DIAMOND clinical trials, specifically investigated the drug's safety in high-risk patients (like those with heart failure). The findings showed that Dofetilide did not increase the risk of all-cause mortality compared to a placebo in these patient groups.


Q: What should be done if an overdose of Dofetilide is suspected?

Official regulatory instructions indicate that emergency medical attention is required immediately in the event of suspected overdose. The primary concern is excessive QT prolongation, which can lead to life-threatening heart rhythm disturbances.


Q: Is Dofetilide a 'blood thinner'?

No, Dofetilide is not a blood thinner (anticoagulant). It is classified as an antiarrhythmic agent, meaning its purpose is to regulate the heart's electrical rhythm, not to reduce the blood's ability to clot.


Q: What should I do if I forget a dose of Dofetilide?

Official administration rules state that if a dose is missed, individuals should continue with the next scheduled dose at the usual time. The rule is to not double the next dose to compensate for the missed one.


Q: Can Dofetilide be taken with or without food?

Yes, official administration guidelines confirm that Dofetilide capsules may be taken with or without food. This means the timing relative to meals does not generally affect the drug's absorption.


Q: Is Dofetilide a newer or older medication?

Pharmacological studies related to Dofetilide span several decades, and the medication has been extensively studied in clinical trials, establishing its use as a treatment for heart rhythm disorders.


Q: Can Dofetilide be split or crushed?

Dofetilide is supplied as an oral capsule for administration. The official product information does not include instructions for crushing or splitting, and capsules are typically designed to be swallowed whole to ensure the intended release into the body.


Q: Is Dofetilide a maintenance medicine or a temporary one?

Dofetilide is indicated for the maintenance of normal sinus rhythm after a heart rhythm disturbance has been corrected. Research has evaluated its use over long periods, confirming its role as a potential maintenance medication.

How should Dofetilide be stored and disposed of?

Dofetilide Storage and Disposal Instructions

Storage Requirements

Dofetilide capsules must be stored at Controlled Room Temperature, specifically 15 C to 30 C (59 F to 86 F), as specified by official labeling. The medication must be protected from moisture and humidity and kept in its tightly closed container to maintain stability. It must be stored out of the reach of children and pets at all times.

Disposal Instructions

Do not keep medicine that is expired or no longer needed. The official regulatory instruction is to ask a healthcare professional or pharmacist how to properly discard any unused Dofetilide. Unused capsules should be handled according to local pharmaceutical waste guidelines or a drug take-back program if available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dofetilide found in:

A-Z Index: